IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v25y2007i1p55-71.html
   My bibliography  Save this article

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children

Author

Listed:
  • Mark Nuijten
  • Wolfgang Wittenberg
  • Maximilian Lebmeier

Abstract

This study suggests that palivizumab prophylaxis against severe RSV infection in children at high risk may be cost effective from the NHS perspective (vs no prophylaxis), and that the positive clinical and economic benefits may persist beyond one RSV season. Copyright Adis Data Information BV 2007

Suggested Citation

  • Mark Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier, 2007. "Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children," PharmacoEconomics, Springer, vol. 25(1), pages 55-71, January.
    • Handle: RePEc:spr:pharme:v:25:y:2007:i:1:p:55-71
    DOI: 10.2165/00019053-200725010-00006
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200725010-00006
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200725010-00006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gareth Thomas, 2018. "A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 177-187, March.
    2. Koen B Pouwels & Sefika E Bozdemir & Selen Yegenoglu & Solmaz Celebi & E David McIntosh & Serhat Unal & Maarten J Postma & Mustafa Hacimustafaoglu, 2016. "Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-15, September.
    3. Anthony Bentley & Ivana Filipovic & Katherine Gooch & Katharina Büsch, 2013. "A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom," Health Economics Review, Springer, vol. 3(1), pages 1-12, December.
    4. Mark Nuijten & Wolfgang Wittenberg, 2010. "Cost effectiveness of palivizumab in Spain: an analysis using observational data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 105-115, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 261-271, July.
    2. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    3. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    4. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    5. Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.
    6. Gre[ss], Stefan & Niebuhr, Dea & Rothgang, Heinz & Wasem, Jurgen, 2005. "Criteria and procedures for determining benefit packages in health care: A comparative perspective," Health Policy, Elsevier, vol. 73(1), pages 78-91, July.
    7. Cairns, John, 2006. "Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared," Health Policy, Elsevier, vol. 76(2), pages 134-143, April.
    8. Dakin, Helen Angela & Devlin, Nancy J. & Odeyemi, Isaac A.O., 2006. ""Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making," Health Policy, Elsevier, vol. 77(3), pages 352-367, August.
    9. repec:ces:ifodic:v:4:y:2006:i:2:p:14567506 is not listed on IDEAS
    10. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    11. Tappenden, P & Brazier, J & Ratcliffe, J, 2006. "Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A," MPRA Paper 29772, University Library of Munich, Germany.
    12. Williams, Iestyn & Bryan, Stirling, 2007. "Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual framework," Health Policy, Elsevier, vol. 80(1), pages 135-143, January.
    13. Henderson, John & Janke, Katharina & Propper, Carol, 2007. "Are current levels of air pollution in England too high?: the impact of pollution on population mortality," LSE Research Online Documents on Economics 6205, London School of Economics and Political Science, LSE Library.
    14. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    15. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
    16. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    17. Mauskopf, Josephine & Chirila, Costel & Birt, Julie & Boye, Kristina S. & Bowman, Lee, 2013. "Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: Have they impacted the National Health Service budget?," Health Policy, Elsevier, vol. 110(1), pages 49-59.
    18. E. Stolk & M. Poley, 2005. "Criteria for determining a basic health services package," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 2-7, March.
    19. Colin Green & Karen Gerard, 2009. "Exploring the social value of health‐care interventions: a stated preference discrete choice experiment," Health Economics, John Wiley & Sons, Ltd., vol. 18(8), pages 951-976, August.
    20. Hodgetts, Katherine & Elshaug, Adam G. & Hiller, Janet E., 2012. "What counts and how to count it: Physicians’ constructions of evidence in a disinvestment context," Social Science & Medicine, Elsevier, vol. 75(12), pages 2191-2199.
    21. Michael Drummond, 2012. "Economic Evaluation and Decision-makers," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 54, Edward Elgar Publishing.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:25:y:2007:i:1:p:55-71. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.